Nexira Group has acquired Tournay Biotechnologies, a European extractor of active botanicals for the nutraceutical and dietary supplements industries. The acquisition enables Nexira to expand its range of ingredients and reinforce its positioning towards the health and wellness market, which will soon represent 35% of its commercial activity. Nexira growth target is 125 million euros in consolidated sales by 2015.
Tournay Biotechnologies, a family owned company founded in 1992, produces extracts including cranberry, green coffee and green tea. The company has an ISO 22000 certified and state-of-the-art manufacturing facility located near Bordeaux, France, responsible for an extensive product portfolio including their flagship brand Exocyan™, a line of cranberry extracts standardized on proanthocyanidines (PACs) content. PACs are condensed tannins, a type of flavonoid, with antioxidant and other health activities.
“We are pleased to welcome the Tournay Biotechnologies personnel, with whom we share family values. We are confident that this acquisition is aligned with the expansion plan that we announced one year ago,” said Stéphane Dondain, president of Nexira.
“The acquisition of Tournay Biotechnologies by Nexira will give to the company an international dimension, essential to accelerate its expansion,” added Cédric Tournay, president of Tournay Biotechnologies
The transaction terms that will be finalized at the end of October were not disclosed.